Fig. 2

Surface activation marker and BCR signalling analysis of the B-cell subpopulation in new-onset RA patients (n = 27) and RA patients in remission after JAKi treatment (n = 31) compared to healthy controls (n = 23). (a) A representative histogram demonstrating the MFI of CD40; proportions of CD80, CD95, and CD21^low; and the MFI of AKT and SYK phosphorylation 5 min after stimulation with an antibody against BCR in healthy controls and untreated patients and patients with remission of RA after JAKi treatment. Comparative analysis of (b) the MFI of CD40, (c) proportions of CD80, (d) proportions of CD95, (e) proportions of CD21^low, (f) the MFI of pAKT, and (g) the MFI of pSYK on switched, nonswitched, naive and DNB cells was conducted in the peripheral blood of healthy controls and patients with untreated RA and RA remission after JAKi treatment. Data are shown in box-whisker plots with individual dots, where boxes represent the 25th to 75th percentiles and the lines within the boxes represent the medians. P values were determined with Mann-Whitney U test using GraphPad Prism 6 (*P < 0.05, **P < 0.01, ***P < 0.001)